Physician profile
David Alameda
NPI 1962408864
$743.74
in general payments reported to CMS, 2019-2025
12 companies · $35.32 in 2025
The $35.32 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $208 · 2021: $42.40 · 2023: $40.01 · 2024: $71.91 · 2025: $35.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $260.91 | 2019-2020 | |
| Organogenesis INC. | $87.64 | 2020-2025 | Apligraf |
| Misonix INC | $77.97 | 2019-2021 | |
| Novo Nordisk INC | $61.48 | 2019 | |
| Stryker Corporation | $56.41 | 2024 | Viaflow, Augment Injectable |
| Trilliant Surgical LLC. | $55.01 | 2019 | |
| Amgen INC. | $48.87 | 2019 | |
| Access Pro Medical, LLC | $40.01 | 2023 | Matriderm |
| Treace Medical Concepts, INC. | $15.50 | 2024 | |
| Tactile Systems Technology INC | $14.69 | 2019 | |
| Bioventus LLC | $13.65 | 2020 | |
| Merck Sharp & Dohme LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alameda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.